Original InvestigationComparison of the Quantitative CT Imaging Biomarkers of Idiopathic Pulmonary Fibrosis at Baseline and Early Change with an Interval of 7 Months
Section snippets
Patient Selection
A total of 57 subjects (45 males, 12 females, with mean FVC 65 ± 12%, DLCO 50 ± 14%) were selected from an imaging database of standardized CT scans with at least two scans obtained from patients with well-characterized IPF whose baseline scan dates ranged from January 2011 to September 2012. Diagnosis of IPF was based on the American Thoracic Society, European Respiratory Society, and Latin American Thoracic Association statement and was confirmed by HRCT and/or surgical lung biopsy (10). Of
Descriptive Summary Statistics
Mean duration between two CT scans was 7 months with standard deviation of 1.8 months. Table 1 lists mean, standard deviation, median, and interquartile range at baseline and follow-up of all three types of measures: PFT, CT histogram indices, and quantitative CT texture scores. It is recognized that most subjects demonstrate either stable or progressive disease over the period of study (mean of 7 months). Most of the measures showed statistically significant changes between baseline and
Discussion
For a quantitative imaging biomarker to be used as a predictive or surrogate outcome it must be shown to be robust enough to be implemented at multiple sites, reproducible, and related to clinically meaningful outcomes 36, 37. Quantitative CT has been used to measure the amount of lung involvement in patients with diffuse lung disease including nonspecific interstitial pneumonia and IPF. In patients with IPF the disease can vary from insidious and stable over time to being rapidly progressive
References (43)
- et al.
Idiopathic pulmonary fibrosis: diagnosis and epidemiology
Clin Chest Med
(2012) - et al.
Pathogenesis, current treatment and future direction for idiopathic pulmonary fibrosis
Curr Opin Pharmacol
(2013) Quantitative CT of fibrotic interstitial lung disease
Chest
(2007)- et al.
Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life
Chest
(2007) - et al.
High resolution multidetector CT-aided tissue analysis and quantification of lung fibrosis
Acad Radiol
(2007) - et al.
Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study
Acad Radiol
(2008) - et al.
Reproducibility of lung and lobar volume measurements using computed tomography
Acad Radiol
(2010) - et al.
Determinants of survival in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
(1994) - et al.
Incidence and prevalence of idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
(2006) - et al.
Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis
Respir Med
(2001)
Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality
Am J Respir Crit Care Med
A multidimensional index and staging system for idiopathic pulmonary fibrosis
Ann Intern Med
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography
Am J Respir Crit Care Med
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends
Am J Respir Crit Care Med
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
Am J Respir Crit Care Med
Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature
Am J Respir Crit Care Med
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials
Am J Respir Crit Care Med
Interstitial lung disease
Eur Respir Rev
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
Drug Des Devel Ther
Current and novel drug therapies for idiopathic pulmonary fibrosis
Drug Des Devel Ther
Cited by (95)
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
2023, Immunology and Allergy Clinics of North AmericaA Convolutional Neural Network Approach to Quantify Lung Disease Progression in Patients with Fibrotic Hypersensitivity Pneumonitis (HP)
2022, Academic RadiologyCitation Excerpt :Indexes derived from frequency histograms of lung CT scans are quantitative and reproducible features, which have shown sensitivity to disease severity and progression (12,13). Analysis of the lung parenchyma based on machine learning and deep learning techniques has rapidly advanced in recent years, providing characterization of lung texture and the relative contribution of different disease patterns (14–21). In particular, deep learning approaches for ILD pattern recognition and classification have achieved impressive results (22,23).
Explainability of radiomics through formal methods
2022, Computer Methods and Programs in BiomedicineAutomated Computed Tomography Lung Densitometry in Bronchiectasis Patients
2022, Archivos de Bronconeumologia
Funding information: NIH NHLBI R01 HL 072424.